Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

Kura Oncology to Participate in JMP Securities Life Sciences Conference

GlobeNewswire May 9, 2023

Kura Oncology to Report First Quarter 2023 Financial Results

GlobeNewswire May 3, 2023

Kura Oncology to Participate in Stifel Targeted Oncology Days

GlobeNewswire April 18, 2023

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

GlobeNewswire April 17, 2023

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

GlobeNewswire March 14, 2023

Kura Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire March 1, 2023

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 23, 2023

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 16, 2023

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

GlobeNewswire February 9, 2023

Kura Oncology to Participate in SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

GlobeNewswire January 24, 2023

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

GlobeNewswire December 10, 2022

Kura Oncology to Host Investor Event on December 10, 2022

GlobeNewswire December 1, 2022

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 22, 2022

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

GlobeNewswire November 3, 2022

Kura Oncology Reports Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

GlobeNewswire November 3, 2022

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 2, 2022

Kura Oncology to Report Third Quarter 2022 Financial Results  

GlobeNewswire October 27, 2022

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

GlobeNewswire October 26, 2022